SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

1. Name and Address of Reporting Person* $\underline{Neff \ Thomas \ B}$			2. Issuer Name and Ticker or Trading Symbol <u>FIBROGEN INC</u> [FGEN]		tionship of Reporting Pe all applicable) Director	rson(s) to Issuer 10% Owner
(Last) C/O FIBROGEI 409 ILLINOIS S	(First) (Middle) FIBROGEN, INC. ILLINOIS ST.		3. Date of Earliest Transaction (Month/Day/Year) 08/01/2018	X	Officer (give title below) Chief Executiv	Other (specify below) e Officer
(Street) SAN FRANCISCO (City)	CA (State)	94158 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filir Form filed by One Rep Form filed by More tha Person	porting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Of (D) (Instr. 3, 4 and Code (Instr.			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(instr. 4)
Common Stock	08/01/2018		М		10,320	A	\$3.6	2,804,873	D	
Common Stock	08/01/2018		S		13,660 ⁽¹⁾	D	\$62.95 ⁽²⁾	2,791,213	D	
Common Stock	08/01/2018		S		5,240 ⁽¹⁾	D	\$ 63.54 ⁽³⁾	2,785,973	D	
Common Stock	08/01/2018		S		918 ⁽¹⁾	D	\$ 63.08 ⁽⁴⁾	103,056	I	By Family Partnership
Common Stock	08/02/2018		М		10,320	A	\$3.6	2,796,293	D	
Common Stock	08/02/2018		S		11,600 ⁽¹⁾	D	\$62.71 ⁽⁵⁾	2,784,693	D	
Common Stock	08/02/2018		S		7,300 ⁽¹⁾	D	\$63.19 ⁽⁶⁾	2,777,393	D	
Common Stock	08/02/2018		S		918 ⁽¹⁾	D	\$62.88 ⁽⁷⁾	102,138	I	By Family Partnership
Common Stock								19,500	Ι	By Spouse
Common Stock								60,946	Ι	See footnote ⁽⁸⁾

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(3,	• •											
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exerc Expiration Da (Month/Day/)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$3.6	08/01/2018		М			10,320	(9)	03/11/2019	Common Stock	10,320	\$0.00	278,621	D	
Stock Option (Right to Buy)	\$3.6	08/02/2018		М			10,320	(9)	03/11/2019	Common Stock	10,320	\$0.00	268,301	D	

Explanation of Responses:

1. Shares sold pursuant to a 10b5-1 plan.

2. The shares were sold at prices ranging from \$62.45 to \$63.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. The shares were sold at prices ranging from \$63.45 to \$63.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. The shares were sold at prices ranging from \$62.60 to \$63.525. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

5. The shares were sold at prices ranging from \$62.05 to \$63.025. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. The shares were sold at prices ranging from \$63.05 to \$63.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

7. The shares were sold at prices ranging from \$62.25 to \$63.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

8. The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.

9. Fully vested.

Remarks:

<u>/s/ Dorothy Pacini, Attorney-in-</u> <u>fact</u> 08/03/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.